LY2603618 | Potent and selective Chk1 inhibitor
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $50.00 | ||
| 25 mg | $195.00 |
LY2603618 (911222-45-2) is a potent (IC50 = 7nM) and selective (>1000x over Chk2) Checkpoint kinase 1 (Chk1) inhibitor.1 Chk1 is an important regulator of the DNA damage response – combination treatment of LY2603618 with other chemotherapeutic agents significantly increased tumor growth inhibition when compared to chemotherapeutic alone.2,3,4 LY2603618 caused a dramatic suppression of cell growth in MCF-7 and MDA-MB-231 human breast cancer cells via Chk1 inhibition induced upregulation of replication stress caused by oncogenes.5
References/Citations:
1) King et al. (2014), Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor; Invest. New Drugs, 32 213
2) Calvo et al. (2014), Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer; Invest. New Drugs, 32 955
3) Calvo et al. (2016), Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors; Oncology, 91 251
4) Zhao et al. (2016), Inhibition of CHK1 enhances cell death induced by the Bcl-1-selective inhibitor ABT-199 in acute myeloid leukemia cells; Oncotarget, 7 34785
5) Zhang et al. (2016), Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress; Oncotarget, 7 34688
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
LY2603618 (911222-45-2) is a potent (IC50 = 7nM) and selective (>1000x over Chk2) Checkpoint kinase 1 (Chk1) inhibitor.1 Chk1 is an important regulator of the DNA damage response – combination treatment of LY2603618 with other chemotherapeutic agents significantly increased tumor growth inhibition when compared to chemotherapeutic alone.2,3,4 LY2603618 caused a dramatic suppression of cell growth in MCF-7 and MDA-MB-231 human breast cancer cells via Chk1 inhibition induced upregulation of replication stress caused by oncogenes.5
References/Citations:
1) King et al. (2014), Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor; Invest. New Drugs, 32 213
2) Calvo et al. (2014), Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer; Invest. New Drugs, 32 955
3) Calvo et al. (2016), Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors; Oncology, 91 251
4) Zhao et al. (2016), Inhibition of CHK1 enhances cell death induced by the Bcl-1-selective inhibitor ABT-199 in acute myeloid leukemia cells; Oncotarget, 7 34785
5) Zhang et al. (2016), Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress; Oncotarget, 7 34688
Related products
-
Cyclopamine | Inhibits hedgehog signaling
From $56.00CAS:4449-51-8Catalog Number:10-1082Activity:Inhibits hedgehog signalingMolecular Weight:411.63Molecular Formula:C27H41NO2Solubility:Soluble in DMSO (up to 4 mg/ml) or in Ethanol (up to 20 mg/ml)Physical Properties:White solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT -
Ko-143 | BCRP inhibitor
From $110.00CAS:461054-93-3Catalog Number:10-1074Activity:BCRP inhibitorChemical Name:(3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1′,2′:1,6]pyrido [3,4-b]indole-3-propanoic acid 1,1-dimethylethyl esterMolecular Weight:469.59Molecular Formula:C26H35N3O5Solubility:Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 50 mg/ml).Physical Properties:White solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 2 years from date of purchase as supplied. Protect from exposure to moisture. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT -
ZM-447439 | Aurora B kinase inhibitor
From $52.00CAS:331771-20-1Catalog Number:10-1037Activity:Aurora B kinase inhibitorChemical Name:N-[4-[[6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]benzamideMolecular Weight:513.59Molecular Formula:C29H31N5O4Solubility:Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 25 mg/ml).Physical Properties:White solidPurity:98% by TLCStorage Temperature:RTStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
